2.3 Beyond-Use Dates (BUDs), Stability & Packaging
Key Takeaways
- A BUD is the point after which a CNSP must not be used; it cannot exceed applicable stability evidence, the earliest component expiration, packaging capability, storage controls, or a shorter legal limit.
- Current defaults are 90 days for nonaqueous oral liquids, 180 days for other nonaqueous dosage forms, 14 days refrigerated for nonpreserved aqueous dosage forms, and 35 days at room temperature or refrigerated for preserved aqueous dosage forms.
- Preservation addresses microbial growth but does not itself prove chemical or physical stability; nonpreserved and preserved aqueous preparations belong to different default categories.
- A longer BUD requires formulation-specific evidence; aqueous CNSPs extended beyond the default require USP <51> antimicrobial-effectiveness testing, and <795> caps the BUD at 180 days.
- Packaging and storage must protect against light, moisture, evaporation, sorption, leaching, leakage, and route-of-administration errors for the full assigned BUD.
2.3 Beyond-Use Dates (BUDs), Stability & Packaging
Quick Answer: Without formulation-specific stability information, revised USP <795> uses four default BUD categories: 90 days for nonaqueous oral liquids; 180 days for other nonaqueous dosage forms; 14 days refrigerated for nonpreserved aqueous dosage forms; and 35 days at controlled room temperature or refrigerated for preserved aqueous dosage forms. A shorter limit from stability evidence, component expiration, packaging, storage, or law controls.
Expiration Date vs. Beyond-Use Date (BUD)
Understanding the distinction between an Expiration Date and a Beyond-Use Date (BUD) is a fundamental competency tested on the PTCB Nonsterile Compounding exam.
Fundamental Definitions
- Expiration Date: Established by commercial pharmaceutical manufacturers through extensive, FDA-mandated stability testing under Current Good Manufacturing Practice (cGMP). It reflects the date up to which a commercially manufactured drug product in its original, unopened container is guaranteed to maintain identity, strength, quality, and purity.
- Beyond-Use Date (BUD): Assigned by a licensed compounder for a specific Compounded Nonsterile Preparation (CNSP). The BUD indicates the date or time after which the CNSP must not be used, administered, stored, or transported.
Absolute Rule of Component Expiration Limits
The assigned BUD of a CNSP can NEVER exceed the shortest manufacturer expiration date of any individual API, excipient, or vehicle used in the formulation.
Example: If a technician compounds an oral suspension using an API powder expiring in 2 years, an oral vehicle expiring in 1 year, and a flavoring agent expiring in 10 days, the maximum possible BUD for that compound cannot exceed 10 days, regardless of standard USP defaults.
Five Parameters of Pharmaceutical Stability
Stability is defined as the extent to which a compounded drug preparation retains, within specified limits and throughout its period of storage and use, the same properties and characteristics that it possessed at the time of compounding. USP <795> recognizes five core types of stability:
| Stability Parameter | Primary Requirement & Failure Manifestations |
|---|---|
| Chemical Stability | Active drug retains chemical integrity and labeled potency ($>= 90%$ of labeled active strength). Failure: Chemical hydrolysis, oxidation, photolysis, or loss of potency. |
| Physical Stability | Original physical appearance, uniformity, color, odor, viscosity, and particle suspension are preserved. Failure: Phase separation (cracking of emulsions), precipitation, caking of suspensions, liquefaction of powders. |
| Microbiological Stability | Resistance to microbial growth is maintained; antimicrobial preservative efficacy is preserved. Failure: Mold growth, bacterial proliferation, turbidity, odor development. |
| Therapeutic Stability | Therapeutic effect and bioavailability remain completely unaltered throughout shelf life. Failure: Delayed drug release, sub-therapeutic dosing, reduced systemic absorption. |
| Toxicological Stability | No significant increase in toxicity occurs; absence of harmful degradation products. Failure: Formation of toxic degradation byproducts (e.g., degraded tetracycline causing renal Fanconi syndrome). |
Revised USP <795> Default BUD Decision Matrix
The revised USP Chapter <795> (effective November 1, 2023) established an objective, scientific framework for assigning default BUDs to CNSPs stored in tight, light-resistant containers based on water activity ($a_w$), formulation composition, and storage temperature.
Concept of Water Activity ($a_w$)
Water activity ($a_w$) quantifies the amount of unbound, free water available in a formulation to support chemical degradation (such as hydrolysis) and microbial multiplication. Pure water has an $a_w$ of 1.00.
- Low Water Activity ($a_w < 0.60$): Formulations with $a_w < 0.60$ (solids, powders, nonaqueous liquids, fixed oils) suppress microbial growth and slow chemical hydrolysis.
- High Water Activity ($a_w >= 0.60$): Formulations with $a_w >= 0.60$ (aqueous solutions, suspensions, creams, gels) provide an environment conducive to microbial growth and rapid hydrolysis, requiring shorter default BUDs or refrigeration.
Comprehensive USP <795> Default BUD Decision Table
| CNSP Category | Storage Condition | Maximum Default BUD Without Applicable Stability Information |
|---|---|---|
| Nonaqueous oral liquid | Controlled room temperature or refrigerator | 90 days |
| Other nonaqueous dosage form | Controlled room temperature or refrigerator | 180 days |
| Nonpreserved aqueous dosage form | Refrigerator | 14 days |
| Preserved aqueous dosage form | Controlled room temperature or refrigerator | 35 days |
Preserved vs. Nonpreserved Aqueous Preparations
- Nonpreserved aqueous: The 14-day refrigerated default applies regardless of route when no applicable stability information supports another BUD.
- Preserved aqueous: A suitable preservative system permits the 35-day default, but only when compatible with the formulation and route. A preservative does not prove chemical stability or replace microbial-risk controls.
Worked Example: Assigning a BUD
- Scenario: A technician compounds a pediatric spironolactone 5 mg/mL oral suspension using spironolactone tablets, Ora-Plus (suspending vehicle containing water), and Ora-Sweet (flavored vehicle containing water).
- Component Expiration Dates: Spironolactone tablets expire in 18 months; Ora-Plus expires in 12 months; Ora-Sweet expires in 8 days.
- Analysis:
- Determine whether the aqueous vehicle is preserved. For this example, treat it as a nonpreserved aqueous dosage form.
- USP <795> assigns a 14-day refrigerated default BUD to nonpreserved aqueous dosage forms.
- However, Ora-Sweet expires in 8 days.
- Conclusion: The assigned BUD must be 8 days refrigerated, constrained by the earliest expiring component.
Extending BUDs Beyond USP Defaults
A pharmacy may assign an extended BUD exceeding standard USP <795> default limits only if rigorous scientific criteria are met:
Evidence and Tests for a Longer BUD
- Validated Stability-Indicating Analytical Assay: The specific formulation (exact API, excipients, concentrations, and container closure) must have documented chemical stability proven by a stability-indicating High-Performance Liquid Chromatography (HPLC) assay. The assay must differentiate the intact active drug from its degradation products.
- USP-NF Monograph or Peer-Reviewed Literature: The extended BUD must be supported by an official USP-NF compounded preparation monograph or published stability studies in reputable peer-reviewed journals (e.g., American Journal of Health-System Pharmacy, International Journal of Pharmaceutical Compounding).
- Aqueous formulations: A CNSP with a BUD longer than the applicable default must be tested for antimicrobial effectiveness under USP <51>. Even with supporting data, the maximum BUD under <795> is 180 days.
Warning: Do not extrapolate a longer BUD when vehicle, strength, process, packaging, or storage differs materially from the supporting study. Assign the shorter supported BUD and document the source used.
Packaging & Container Closure Systems (USP <659> & USP <661>)
Packaging protects CNSPs from environmental atmospheric exposure, light degradation, moisture permeation, and mechanical damage during storage and transport.
USP Container Classifications (USP <659>)
- Well-Closed Container: Protects the contents from extraneous solids and loss of drug under ordinary conditions of handling, shipment, and storage.
- Tight Container: Protects contents from contamination by extraneous liquids, solids, or vapors; prevents loss of drug and moisture loss or absorption (effervescence or deliquescence). Mandatory for moisture-sensitive solid dosage forms and aqueous liquids.
- Hermetic Container: Impervious to air or any other gas under ordinary conditions.
- Light-Resistant Container: Protects contents from photochemical deterioration caused by light transmission. Must meet USP limits for light transmission (transmitting less than 10% of light between 290 nm and 450 nm wavelength). Typically made of amber glass or opaque amber plastic.
Packaging Materials: Glass vs. Plastic
| Packaging Material | Physical & Chemical Properties | Primary Advantages & Disadvantages |
|---|---|---|
| Type I Glass (Borosilicate) | Highly resistant to chemical leaching and thermal shock | Gold Standard; inert, zero leaching, suitable for all liquids & reactive APIs; fragile & heavy |
| Type II & III Glass (Soda-Lime) | Moderately resistant glass | Used for dry powders, nonaqueous liquids, or topical ointments |
| HDPE Plastic (High-Density Polyethylene) | Rigid, lightweight, opaque/translucent plastic | Excellent moisture barrier; shatterproof; low cost; minor risk of gas permeation |
| PET Plastic (Polyethylene Terephthalate) | Clear, strong plastic with good clarity | Good barrier for oral liquids; sensitive to high heat |
| Polypropylene (PP) | Semi-rigid plastic with high heat resistance | Commonly used for pill bottles, ointment jars, and oral syringes |
Chemical Interaction Risks with Plastic Packaging
- Sorption: The active drug or preservative adsorbs onto or absorbs into the inner plastic container wall, reducing effective drug concentration.
- Leaching: Chemical plasticizers, antioxidants, or stabilizers migrate from the plastic container into the compounded liquid or semisolid preparation.
- Permeation: Atmospheric oxygen, carbon dioxide, or water vapor penetrates through the plastic container walls, causing drug oxidation or evaporation.
Specialized Dispensing Packaging
- Amber Prescription Bottles: Standard container for oral liquid solutions and suspensions.
- Collapsible Ointment Tubes (Aluminum or Plastic): Ideal for creams and ointments; minimizes air exposure during patient use compared to open-mouth jars.
- Topi-Click Dispensers: Metered-dose topical applicators that deliver precise volumes (e.g., 0.25 mL per click) for transdermal hormone gels, preventing hand contamination.
- Amber Oral Syringes: Used for accurate pediatric unit-dosing. Must be affixed with a prominent "FOR ORAL USE ONLY" auxiliary label to prevent accidental intravenous administration.
Storage & Transport Protocols
Compounded preparations must be transported under conditions that maintain temperature integrity and physical stability:
- Cold Chain Transport: CNSPs requiring refrigeration (2°C to 8°C) must be shipped in insulated coolers packed with validated gel ice packs and temperature-monitoring indicator strips.
- Protection from Extreme Temperatures: Formulations must be protected from freezing (which breaks emulsions and causes precipitation) and extreme heat (which melts suppositories and accelerates chemical oxidation).
A technician compounds a nonpreserved aqueous amoxicillin oral suspension. If no applicable stability information supports another BUD, what is the USP <795> default?
According to revised USP <795>, what is the default Beyond-Use Date (BUD) for a nonaqueous compounded ointment prepared with fixed oils and petrolatum (a_w < 0.60) stored at Controlled Room Temperature?
A preserved aqueous hydrocortisone cream otherwise qualifies for the 35-day USP <795> default, but one component expires in 12 days. What BUD may be assigned?
Why must oral liquid compounded doses packaged in oral syringes be affixed with a prominent "FOR ORAL USE ONLY" auxiliary label?